

SECONDSIGHT

Second Sight Medical Products, Inc.
(NASDAQ: EYES)

Discover

Life in a New Light®

First & Only FDA-approved treatment for individuals with severe Retinitis Pigmentosa

Corporate Presentation
April 2019



Forward Looking Statements




This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange and Exchange Act of 1934, as amended, which are intended to be covered by the "safe harbor" created by those sections. All statements in this release that are not based on historical fact are "forward looking statements." These statements may be identified by words such as "estimates," "anticipates," "projects," "plans," or "planned," "seeks," "may," "will," "expects," "intends," "believes," "should," and similar expressions, or the negative versions thereof, and which also may be identified by their context. All statements that address operating performance or events or developments that Second Sight expects or anticipates will occur in the future, such as stated objectives or goals, or that are not otherwise historical facts, are forward-looking statements. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our Annual Report, on Form 10-K, filed on or about March 18, 2019 and our other reports filed from time to time with the Securities and Exchange Commission. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto, or any change in events, conditions, or circumstances on which any such statement is based.

Two Breakthrough Technologies


Argus® II Retinal Prosthesis

- First and only FDA approved retinal prosthesis
- 20+ years and ~\$200 million invested to develop and commercialize
- Established technology with 300+ implants
- Approved for individuals with advanced retinitis pigmentosa (bare-light and no-light perception in U.S.)




Orion® Visual Cortical Prosthesis

- Transformational technology with U.S. human trial initiated in Q1 2018
- Broad label potential for most causes of blindness including glaucoma, diabetic retinopathy, optic nerve disease and trauma
- Bypasses the retina and optic nerve to directly stimulate the portion of the brain responsible for vision



Argus II is a retinal prosthesis that induces visual perception in individuals with advanced retinitis pigmentosa (RP)



Video Link: <https://youtu.be/ezVNM05GeUE>



Execute Orion clinical and R&D programs as our top priority

- Six subject U.S. feasibility study at UCLA and Baylor is ongoing
- R&D efforts to iterate cortical prosthesis and external components in preparation for pivotal trial
- Orion designated FDA Breakthrough Device for expedited pathway to commercialization



Improve the artificial vision user experience

- Multiple research projects to enhance visual acuity and create a richer user experience
- Examples include object and facial recognition, distance filtering, thermal imaging and eye tracking
- Technologies can be integrated in Argus and Orion platforms




Build and leverage commercial capabilities with capital efficiency

- Focus on markets and Centers of Excellence (COE) with near-term ROI and highest impact
- Restructuring completed in Europe to reduce annual commercial spend by approximately \$3 million
- Build market development and artificial vision rehab competencies required for Argus and Orion


Orion[®]: Breakthrough Device with Potential to Treat Virtually All Forms of Blindness

*The addressable market for Orion is potentially over 70,000 individuals in the U.S.;
a multi-billion dollar market opportunity*



Encouraging Orion[®] Early Feasibility Study Results

- Conducting a six subject feasibility study at Ronald Reagan UCLA Medical Center and the Baylor College of Medicine
 - Five subjects implanted and activated in 1H 2018
 - Sixth patient implanted and activated at Baylor College of Medicine in 2019
- Observations from our early testing include the following:
 - Five patients cleared for home use
 - Stimulation parameters are within expected ranges and field of view appears to be larger than Argus
 - Observations from rehab sessions indicate subjects are able to do things with Orion that they could not do without, including:
 - Locate people in front of them
 - Walk down sidewalk and identify parked cars and driveways
 - Identify cue ball and striped balls on a pool table
 - Sort light from dark laundry
 - Identify and blow out candles on birthday cake



Performance data from feasibility patients will be used to determine next steps in 2019 including discussions with FDA to finalize clinical and regulatory pathway as part of Breakthrough Devices program

Research Technologies to Enhance User Experience

Eye Tracking

Move the implant field of view in conjunction with the movement of the user's eyes

Thermal Imaging

Infrared imaging would allow users to visualize warm objects such people in a room



Depth-Based Decluttering

Allow users to filter out objects further than a defined distance

Object & Facial Recognition

Receive additional auditory and/or haptic information integrated with their artificial vision

Research projects have potential to benefit Argus and Orion users

Orion® Leverages our Commercial Experience & Argus II Technology



Centers of Excellence (COE) model and artificial vision rehabilitation

- Centers of Excellence model to build regional artificial vision centers for Argus and Orion
- Best practices development and pioneered post-surgical rehabilitation to improve patient satisfaction and outcomes for all artificial vision patients



Effective patient outreach & screening with U.S. patient database

- Effective patient outreach programs and a multi-step patient qualification process applicable to Argus and Orion
- Large and growing U.S. database that includes potential Argus and Orion patients



Market access & reimbursement expertise benefits Orion


- Argus is an established therapy in over a dozen markets globally
- Achieved highest CMS outpatient reimbursement rate in U.S. at \$152.5k for 2019
- Conducting clinical studies via Forfait Innovation (France) and Commissioning Through Evaluation (England) programs for national reimbursement



Orion leverages Argus II technology platform

- Established technology with 10 years+ proven implant durability
- Proprietary algorithms for artificial vision


Innovative Pipeline Extends our Leadership Position



Key Drivers of Shareholder Value through 2019

Orion

-  Complete Orion feasibility trial and release interim data from first six subjects
-  Agreement on pivotal and post-market trial designs via the FDA's Breakthrough Device Program
-  Initiation of U.S. Orion pivotal trial



Select Financial Data



(USD \$ in thousands)	FY 2018	FY 2017
Implants	69 (16 in Q4)	75 (30 in Q4)
Revenue	\$6,896	\$7,964
Gross Profit (Loss)	\$2,008	\$2,847
Net Loss	\$(35,094)	\$(28,516)
Non-GAAP Adjusted Net Loss ¹	\$(30,777)	\$(27,576)

1) Non-GAAP adjusted net loss excludes non-cash expenses including stock-based compensation and reserve for excess inventory.

(USD \$ in thousands)	December 31, 2018	December 31, 2017
Cash and cash equivalents	\$4,471	\$7,839
<i>Cash balance as of December 31, 2018 does not include \$34.6 million in gross proceeds from February 2019 rights offering</i>		
Debt	\$0	\$0

Second Sight Investment Highlights



- **Orion is a large market opportunity that's more than 50x the current RP market**
 - Potential to treat nearly all forms of blindness including diabetic retinopathy, glaucoma, optic nerve disease and eye injury
 - Six subject feasibility study at UCLA and Baylor underway with good early results and interim data in next six months
 - FDA Breakthrough Device designation provides expedited regulatory and clinical pathway
- **Orion leverages Argus II**
 - Orion leverages Argus technology including implantable array, externals and proprietary software / algorithms for creating artificial vision
 - Orion also leverages reimbursement success, patient outreach and screening expertise as well as artificial vision rehabilitation competencies
- **Future technologies under development beneficial to Argus II and Orion**
 - Eye-tracking, thermal imaging and depth-based decluttering provide improved or more useful vision
 - Object recognition and facial recognition create enhanced user experience
- **Argus II business focused on capital efficiency and strategic benefit**
 - Commercial competencies and R&D efforts such as Argus 2s next-gen externals that benefit Orion are prioritized
 - ROI and cost structure improvements important when evaluating markets or expansion

Second Sight Medical Products, Inc.

12744 San Fernando Road
Suite 400

Sylmar, CA 91342

Main: 818-833-5000

www.secondsight.com

Will McGuire

President & CEO

Direct: 818-833-5040

wmcguire@secondsight.com

Retail Investor Relations

Greg Falesnik

Managing Director

MZ North America

Direct: 949-385-6449

Greg.Falesnik@mzgroup.us

Institutional Investor Relations

Lisa Wilson

President

In-Site Communications, Inc.

Direct: 212-452-2793

lwilson@insitecony.com